All In Biotech

Drug Trial Radar · NCT02772276

Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types

A Pilot Safety and Pharmacokinetic Study of MB-102 Versus Iohexol and the Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types

Last checked: Nov 20, 2026Latest source record: Oct 26, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

234

Actual

Start

May 11, 2016

Primary completion

Aug 4, 2021

Study completion Aug 4, 2021

Sponsor

Lead sponsor
MediBeaconIndustry
Sponsor type
Industry
First posted
May 13, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study was a pilot, safety, and pharmacokinetic study of MB-102 versus iohexol and the use of the non-invasive optical renal function monitor (ORFM) device in normal and compromised renal function participants with different skin color types.

Conditions

  • Acute Kidney Injury

Interventions

  • MB-102-- single dose of 4 µmol/kgDrug

    4 µmol/kg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds.

  • MB-102-- single dose of 130 mgDrug

    130 mg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds. A subset of participants will receive two doses of MB-102, 12 hours apart.

  • MB-102-single dose of 130 mg or 2 doses of 130 mg 12 hours apartDrug

    130 mg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds.

  • MB-102-- two doses of 130 mg 24 hours apartDrug

    4 µmol/kg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds. A subset of participants will receive two doses of MB-102, 12 hours apart.

  • IohexolDrug

    5 mL of a 647 mg/mL solution administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds

  • QuantumLeapDevice

    Optical Renal Function Monitor (ORFM)

  • RadianceDevice

    Optical Renal Function Monitor (ORFM)

  • Brilliance (1 or 2 sensors)Device

    Optical Renal Function Monitor (ORFM)

  • Brilliance (2-part sensor)Device

    Optical Renal Function Monitor (ORFM)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse EventsTime frame: From the time of dosing through the follow-up visit, up to 10 days

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Riverside Clinical Research

    Edgewater, Florida

  • Orlando Clinical Research Center

    Orlando, Florida

  • Washington University School of Medicine

    St Louis, Missouri

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.